| Comprehensive molecular characterization of clear cell renal cell carcinoma Cancer Genome Atlas Research Network Analysis working group: Baylor College ... Nature 499 (7456), 43-49, 2013 | 3575* | 2013 |
| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3181 | 2013 |
| Comprehensive molecular characterization of urothelial bladder carcinoma Cancer Genome Atlas Research Network Nature 507 (7492), 315, 2014 | 2591 | 2014 |
| The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma JK Maranchie, JR Vasselli, J Riss, JS Bonifacino, WM Linehan, ... Cancer cell 1 (3), 247-255, 2002 | 570 | 2002 |
| Belzutifan for renal cell carcinoma in von Hippel–Lindau disease E Jonasch, F Donskov, O Iliopoulos, WK Rathmell, VK Narayan, ... New England Journal of Medicine 385 (22), 2036-2046, 2021 | 357 | 2021 |
| Regulation of HIF prolyl hydroxylases by hypoxia‐inducible factors O Aprelikova, GVR Chandramouli, M Wood, JR Vasselli, J Riss, ... Journal of cellular biochemistry 92 (3), 491-501, 2004 | 281 | 2004 |
| ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma SA Brooks, AR Brannon, JS Parker, JC Fisher, O Sen, MW Kattan, ... European urology 66 (1), 77-84, 2014 | 276 | 2014 |
| Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor JR Vasselli, JH Shih, SR Iyengar, J Maranchie, J Riss, R Worrell, ... Proceedings of the National Academy of Sciences 100 (12), 6958-6963, 2003 | 205 | 2003 |
| Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy I Tamaskar, JA Garcia, P Elson, L Wood, T Mekhail, R Dreicer, BI Rini, ... The Journal of urology 179 (1), 81-86, 2008 | 186 | 2008 |
| Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma J Riss, C Khanna, S Koo, GVR Chandramouli, HH Yang, Y Hu, DE Kleiner, ... Cancer research 66 (14), 7216-7224, 2006 | 143 | 2006 |
| Nox4 is critical for hypoxia-inducible factor 2-α transcriptional activity in von Hippel-Lindau–deficient renal cell carcinoma JK Maranchie, Y Zhan Cancer research 65 (20), 9190-9193, 2005 | 141 | 2005 |
| Integrin αvβ3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis LM Knowles, LA Gurski, C Engel, JR Gnarra, JK Maranchie, J Pilch Cancer research 73 (20), 6175-6184, 2013 | 125 | 2013 |
| Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant JK Maranchie, BT Bouyounes, PL Zhang, MA O’DONNELL, ... The Journal of urology 163 (3), 748-751, 2000 | 119 | 2000 |
| Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location JK Maranchie, A Afonso, PS Albert, S Kalyandrug, JL Phillips, S Zhou, ... Human mutation 23 (1), 40-46, 2004 | 117 | 2004 |
| Chloroquine-inducible Par-4 secretion is essential for tumor cell apoptosis and inhibition of metastasis R Burikhanov, N Hebbar, SK Noothi, N Shukla, J Sledziona, N Araujo, ... Cell Reports 18 (2), 508-519, 2017 | 72 | 2017 |
| NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α JL Gregg, RM Turner, G Chang, D Joshi, Y Zhan, L Chen, JK Maranchie Cancer research 74 (13), 3501-3511, 2014 | 72 | 2014 |
| TLR4-NOX4-AP-1 signaling mediates lipopolysaccharide-induced CXCR6 expression in human aortic smooth muscle cells DN Patel, SR Bailey, JK Gresham, DB Schuchman, JH Shelhamer, ... Biochemical and biophysical research communications 347 (4), 1113-1120, 2006 | 70 | 2006 |
| Clinical implications of hypoxia inducible factor in renal cell carcinoma MC Smaldone, JK Maranchie Urologic Oncology: Seminars and Original Investigations 27 (3), 238-245, 2009 | 68 | 2009 |
| AUA white paper on implementation of shared decision making into urological practice DV Makarov, K Chrouser, JL Gore, J Maranchie, ME Nielsen, C Saigal, ... Urology practice 3 (5), 355-363, 2016 | 63 | 2016 |
| Phase II study of the oral HIF-2 alpha inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma. E Jonasch, F Donskov, O Iliopoulos, WK Rathmell, V Narayan, ... | 52 | 2020 |
